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 Background: Human fetuin A (AHSG) has been associated with the development of obesity, insulin resistance, type 2 dia-
betes mellitus, and atherosclerosis. Observations on the role of AHSG rs4918 single-nucleotide polymorphism 
are contradictory. We investigated the association between variants of rs4918 and parameters of obesity, lip-
id status, tumor necrosis factor-a (TNFa), adipokines (adiponectin, resistin, leptin), and insulin resistance in 
healthy persons and in patients with previous myocardial infarction.
 Material/Methods: This was a cross-sectional study comprising cohort 1 (81 healthy individuals) and cohort 2 (157 patients with pre-
vious myocardial infarction). We used the allele-specific KASP genotyping assay to detect rs4918 polymorphism.
 Results: In cohort 1, G-nucleotide carriers had significantly lower serum TNFa, adiponectin, and higher leptin concentra-
tions than in non-G carriers. These differences, however, were not observed in cohort 2. In cohort 2, G-carriers 
had lower BMI and waist circumferences than in non-G carriers. The G allele was more frequent among lean 
than obese patients (RR=1.067, 95%CI=1.053–2.651, p=0.015). An association between BMI and rs4918 poly-
morphism was observed among patients without diabetes (CC/CG/GG genotypes: p=0.003, G vs. non-G allele: 
p=0.008) but not in diabetics. In addition, a strong linearity between BMI and the CC/CG/GG genotypes (asso-
ciation value: 4.416, p=0.036) and the frequency of the G allele (7.420, p=0.006) could be identified. In cohort 
2, non-obese, non-diabetic G-carriers still had lower BMI and waist circumferences than in non-G carriers.
 Conclusions: The rs4918 minor variant is associated with lower TNFa and adiponectin, higher leptin levels in healthy per-
sons, and more favorable anthropomorphic parameters of obesity in cohort 2.
 MeSH Keywords: alpha-2-HS-Glycoprotein • Diabetes Mellitus • Myocardial Infarction • Obesity • 
Polymorphism, Single Nucleotide
 Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/896232
Authors’ Contribution: 
Study Design A
 Data Collection B
 Statistical Analysis C
Data Interpretation D
 Manuscript Preparation E
 Literature Search F
Funds Collection G
1 3rd Department of Internal Medicine, Semmelweis University, Budapest, Hungary
2 Department of Family Medicine, Semmelweis University, Budapest, Hungary
3 Department of Internal Medicine, Károlyi Sándor Municipal Hospital, Budapest, 
Hungary
4 Atherosclerosis Research Group of Hungarian Academy of Sciences, Budapest, 
Hungary
5 Department of Genetics and Immunology, and Cell Sciences, Semmelweis 
University, Budapest, Hungary
6 Department of Public Health, Semmelweis University, Budapest, Hungary
e-ISSN 1643-3750
© Med Sci Monit, 2016; 22: 2742-2750
DOI: 10.12659/MSM.896232
2742
Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System]  
[ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica]  
[Chemical Abstracts/CAS]
CLINICAL RESEARCH
This work is licensed under Creative Common Attribution-
NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background
Alpha2HS-glycoprotein/human fetuin A (AHSG) is a multi-
functional glycoprotein secreted by liver parenchymal cells in 
adults [1]. The molecule is a negative acute phase reactant [2] 
and inhibits extraosseal calcification [3]. Its decreased serum 
levels predict mortality of patients with liver cirrhosis [4] and 
end-stage renal disease [5].
The molecule is a natural inhibitor of insulin receptor tyro-
sine kinase, thus AHSG plays a role in the development of in-
sulin resistance [6–9]. Obesity [10], type 2 diabetes mellitus 
(T2DM) [11–13], metabolic syndrome [14], adipocyte dysfunc-
tion [15] and fatty liver [9,16] have been linked to elevated se-
rum AHSG concentration.
At the molecular level, the synthesis of AHSG is enhanced by 
free fatty acids (FFAs) via the nuclear factor kB (NFkB) [15]. The 
AHSG molecule binds to FFA [17]. By binding to the Toll-like re-
ceptor 4 (TLR4), the FFA-AHSG complex generates inflamma-
tory signals and insulin resistance [17]. Serum AHSG and FFA 
interact with each other in predicting insulin sensitivity [18].
Several SNP-s of AHSG have been studied. Serum AHSG con-
centration has been linked with the rs4917 [19–22], the AHSG 
1–2 [23], and polymorphism of the molecule. The rs4917 SNP 
has been associated with obesity [22,24,25], T2DM [26,27], ath-
erosclerosis, and mortality [19,27]. In these studies the minor 
variants seemed to be protective. Others did not find such as-
sociations in these clinical settings [26,28–30]. Dyslipidemia has 
been associated with the –469 T/G (rs2077119) SNP [26,28].
The minor variant of the SNP rs2248690 was associated with 
lower AHSG concentrations but not with the higher risk of di-
abetes [27,31]. This SNP in the promoter region of the AHSG 
gene seems to affect the AHSG gene transcription, possibly by 
producing different associations with AP-1 [32]. A strong link-
age between the rs224869, rs4917, and the risk of myocardial 
infarction has been observed in the EPIC Potsdam Study [19]. 
Others found no association between AHSG variants rs4917, 
rs2248690, and rs2518136, and clinical atherosclerosis [33]. 
In a magnetic resonance study, AHSG variation was not as-
sociated with regional body fat distribution AHSG but it was 
with the whole body fat composition [20].
Reports on AHSG rs4918 (Thr256Ser) polymorphism in exon 7 
are less inconsistent. Lavebratt et al. reported a higher frequen-
cy of the G allele among lean Swedish men [22]. Others found 
the G allele less advantageous. The rs4918 G allele was associ-
ated with high mortality in renal transplant patients [34], and 
conferred higher risk for ischemic stroke than the C allele [35].
In this study we intended to determine the association of the 
alleles in rs4918 SNP of AHSG with parameters of obesity 
(BMI), lipid status (total cholesterol, LDL cholesterol, HDL cho-
lesterol, and triglyceride), proinflammatory cytokines (TNFa), 
and adipokines (adiponectin, resistin, and leptin), in two un-
related groups of individuals, i.e., among healthy persons (co-
hort 1) and patients surviving myocardial infarction (cohort 2).
Material and Methods
Cohorts
Cohort 1 consisted of 82 healthy individuals (17 men, 65 wom-
en, age: 60.1±6.9 years, mean±SD, range: 42–79) who met the 
inclusion criteria: healthy status by physical examination, com-
parable age to group 2, BMI below 30 kg/m2, and normal re-
sults during routine laboratory analysis. These individuals were 
selected from a larger group of patients as described earlier 
[25]. The male/female ratios according to the genotypes were: 
CC: 8/31, CT: 7/25, and TT: 2/8.
Cohort 2 consisted of 157 patients with previous myocardial 
infarction (103 men, 54 women, age: 59.4±12.2 years, range: 
37–85). Only cases with ST-elevation (STEMI) occurring 6–24 
months before the start of the study were investigated. The 
diagnosis of STEMI was established by the alteration of elec-
trocardiography and troponin. Exclusion criteria were: clinical 
or laboratory signs of acute infection, malignant tumor, hepatic 
disease, renal failure, immune suppression, and severe medi-
cal or surgical conditions such as myocardial infarction with-
in 6 months, stroke (at any time), trauma, or surgical proce-
dures. There were 48 patients with diabetes mellitus (all with 
type 2 diabetes [T2DM], diagnosed according to WHO criteria) 
and were treated with diet, metformin, and bedtime insulin. 
Sixty-five percent of patients in cohort 2 received statins and 
70% of them received aspirin. Cohort 2 also included 42 obese 
(BMI ³30 kg/m2) and 115 non-obese patients. The male/fe-
male ratios according to the genotypes were: CC: 48/30, CT: 
40/18, and TT: 15/6.
The study was approved by the local Ethics Committee of the 
Károlyi Sándor Municipality Hospital. All persons gave their in-
formed consent prior to their inclusion in the study.
Genotyping
The single-nucleotide polymorphism (SNP) rs 4918 genotyp-
ing was carried out using the Kompetitive Allele Specific PCR 
genotyping system assay (KASPTM) (LGC Genomics, Berlin, 
Germany) according to the manufacturer’s instructions and 
also described by us earlier [25]. Polymerase chain reaction 
(PCR) conditions included 20 ng of genomic DNA per sample 
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in a total volume of 8 µl and 37 temperature cycles. PCR reac-
tion was carried out by a 7900HT Fast Real-Time PCR System 
(Life Technologies). Classical three-cluster pattern for a SNP 
was considered successful and polymorphic. The genotyping 
was monitored by using 9 samples (3 parallels for CC, CT, and 
TT genotypes, each) in every measurement. These genotypes 
were also determined by KASPTM. The success rate of geno-
type calls was >99%.
Determination of other laboratory parameters
Serum AHSG concentration by radial immunodiffusion (RID) 
was as previous described elsewhere [36]. Intra-assay (IACV) 
and interassay IECV) coefficients of variation were below 5%. 
Adiponectin levels were measured with radioimmunoassay 
(IACV: 3.86%, IECV: 8.47%; Linco Research, St Charles, MO, 
USA). Serum tumor necrosis factor-a (TNFa, Sigma, St Louis, 
MO, USA; IACV: 4.8%, IECV: 6.7%), resistin (Linco Research 
Inc., IACV: 4.0%, IECV: 7.0%), and leptin (DRG International, 
Mountainside, NJ, USA, IACV%: 4.6%, IECV%: 6.6%) were mea-
sured by ELISA.
Fasting levels of serum glucose, total cholesterol, low-density 
(LDL) cholesterol, high-density (HDL) cholesterol, and triglyc-
erides were detected by routine chemical laboratory methods. 
Insulin concentration was measured by insulin direct human 
ELISA kit (Invitrogen, Camarillo, CA, USA, lowest detectable 
concentration 0.17 µIU/ml, IACV: 4.8%, IECV: 81%). C-peptide 
was measured by RIA (Biodata, Rome, Italy, lowest detectable 
concentration: 0.2 ng/ml, IACV: 5.6%, IECV: 7.3%).
rs4918 polymorphism* Nucleotide count Nucleotide frequency**
CC CG GG Total C G C G
Cohort 1 39 32 10 81 110 52 0.679 0.321
Cohort 2 81 61 15 157 223 91 0.710 0.290
Table 1. Allelic distribution of cohorts 1 and 2.
Chi2=0.528, p=0.768.
Parameter
CC homozygotes
(n=39)
CG heterozygotes
(n=32)
GG homozygotes
(n=10)
p*
AHSG (mg/l)  605±84  627±85  613±117 0.185
BMI (kg/m2)  23.9±1.7  24.1±1.4  24.5±1.6 0.257
Abdominal circumference (cm)  87±11  88±8  87±10 0.872
Total cholesterol (mmol/l)  4.98±1.07  4.96±0.83  5.13±1.35 0.930
LDL-cholesterol (mmol/l)  3.13±0.64  2.65±0.82  1.93±0.40 0.292
HDL-cholesterol (mmol/l)  1.39±0.20  1.54±0.27  1.49±0.41 0.597
Triglyceride (mmol/l)  1.85±1.13  1.71±0.88  1.64±0.75 0.950
TNFa (pg/ml)  4.11±0.25  4.10±0.20  3.85±0.22
0.013
0.007**
Adiponectin (µg/ml)  12.3±3.37  12.7±2.87  14.3±2.30 0.131
Resistin (ng/ml)  6.64±2.24  5.76±2.67  6.96±3.52 0.264
Leptin (ng/ml)  10.7±9.2  13.8±9.2  14.1±9.8 0.109
C-peptide (ng/ml)  1.07±0.31  1.15±0.42  1.07±0.29 0.247
Glucose (mmol/l)  4.58±0.42  4.39±0.36  4.22±0.34 0.052
Insulin (µU/ml)  5.30±1.16  5.05±0.99  5.62±0.93 0.348
Table 2. Cohort 1: Comparison of the genotypes of rs4918 (mean ±SD).
* Kruskal-Wallis test in all parameters; **CC vs. GG, when post hoc p<0.05
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Statistical analysis
Statistical analysis was carried out using the SPSS v.21 statisti-
cal software (SPSS Inc., Chicago, IL, USA). Non-parametric meth-
ods, including the Bonferroni (Dunn) post-hoc test, were used.
Results
The allele frequencies did not differ between the two cohorts 
(Table 1).
Cohort 1. Association of the rs4918 alleles with 
parameters of obesity
Anthropologic and laboratory parameters of cohort 1 are shown 
in Table 2. During multiple comparisons we observed significant 
differences in TNFa levels only. Compared to non-G carriers 
(n=39), the presence of the G nucleotide (n=42) was associat-
ed with lower TNFa (3.85±0.22 vs. 4.10±0.23 pg/ml, p=0.003), 
higher leptin (13.9±9.23 vs. 10.7±9.19 ng/ml, p=0.036), and low-
er adiponectin levels (12.4±3.14 vs. 14.3±2.30 µg/ml, p=0.047).
Cohort 2. Association of the rs4918 alleles with 
parameters of obesity
On multiple comparisons we found significant differences 
in waist circumference (Table 3). There was a trend towards 
lower values of obesity in patients with the G allele. Indeed, 
G-carriers (n=76) had significantly lower BMI (27.3±4.6 vs. 
28.6±3.8 kg/m2, p=0.017) and waist circumference (102±9 
vs. 106±8 cm, p=0.002) than those without the G nucleotide 
(n=81). Other parameters, including abdominal circumference 
(101±12 vs. 104±10 cm, p=0.168), did not differ significantly.
Comparison of diabetic and non-diabetic individuals in 
cohort 2
There were 48 patients with T2DM in cohort 2. They differed 
from the non-diabetic individuals (n=109) only in parameters 
of insulin resistance – glucose (7.08±1.99 vs. 5.03±0.68 mmol/l, 
p<0.001), insulin (28.4±16.4 vs. 21.7±14.8 µU/ml, p=0.008), 
C-peptide (3.93±2.27 ng/ml vs. 3.00±2.13 ng/ml, p=0.008), 
HOMA A (7.62±3.45 vs. 4.67±3.04 p<0.001), and HOMA B 
(194±133 vs. 260±147, p=0.004), but not in those of obesity 
– BMI (28.8±4.51 vs. 27.7±3.93 kg/m2, p=0.187), abdominal 
Parameter
CC homozygotes 
(n=81)
CG heterozygotes 
(n=61)
GG homozygotes 
(n=15)
p*
AHSG (mg/l)  682±125  680±94  611±102 0.185
BMI (kg/m2)  28.6±3.8  27.2±4.5  27.5±5.0
0.048
0.204**
Abdominal circumference (cm)  103±10  101±12  100±11 0.333
Waist circumference (cm)  106±8  102±9  102±9
0.005
0.026**
Total cholesterol (mmol/l)  5.38±1.26  5.10±1.13  5.43±1.25 0.673
LDL-cholesterol (mmol/l)  3.23±0.97  3.11±0.96  3.32±0.76 0.618
HDL-cholesterol (mmol/l)  1.23±0.28  1.20±0.27  1.10±0.27 0.112
Triglyceride (mmol/l)  1.90±1.17  1.76±0.80  1.66±0.58 0.934
TNFa (pg/ml)  6.07±1.70  6.15±1.88  5.89±1.75 0.848
Adiponectin (µg/ml)  9.29±4.13  8.63±4.30  8.53±3.21 0.486
Resistin (ng/ml)  9.24±5.73  10.19±7.11  8.93±4.03 0.756
Leptin (ng/ml)  32.2±19.3  29.2±18.0  31.0±10.6 0.676
C-peptide (ng/ml)  3.36±2.26  3.05±1.79  3.87±3.35 0.866
Glucose (mmol/l)  5.51±1.68  5.93±1.74  5.43±0.75 0.275
Insulin (µU/ml)  24.2±16.0  22.1±12.9  27.6±22.6 0.850
Table 3. Cohort 2: Comparison of the genotypes of rs4918 (mean ±SD).
* Kruskal-Wallis test in all parameters; ** CC vs. GG, when post hoc p<0.05
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circumference (104±12 vs. 101±10 cm, p=0.200), or waist cir-
cumference (105±10 vs. 104±8 cm, p=0.510). Due to the small 
size of the minor allele G among diabetics, statistical analy-
sis could not be done among CC (n=24), CG (n=21), and GG 
(n=3) variants. Comparison of C- (n=45) with non-C (n=3) or 
G- (n=24) with non-G-carriers (n=24) showed no significant 
differences in the diabetic group (data not shown).
In patients without diabetes, we found no significant differ-
ences between CC and GG homozygotes. On the other hand, 
G-carriers (n=52) had lower serum AHSG (602±108 vs. 676±110 
mg/l, p=0.043), BMI (26.4±4.0 vs. 28.7±3.8 kg/m2, p=0.001), and 
waist circumference (100±7 vs. 106±8 cm, p<0.001) and mild-
ly lower abdominal circumference values (99±11 vs. 103±10 
cm, p=0.068) than non-G carriers (n=57).
Comparison of obese and non-obese individuals in 
cohort 2
Forty-eight patients were clinically overweight or obese as de-
fined by BMI ³30 kg/m2. They differed from non-obese individu-
als only in BMI, abdominal and waist circumferences, waist/hip 
ratio, and TNFa, but not in other parameters (Table 4). Serum 
AHSG and resistin concentrations were also marginally high-
er in obese than in non-obese patients.
Nineteen percent (12/64) of the lean individuals carried the 
GG genotype in contrast to 9% (3/32) of obese patients. 
Accordingly, the minor allele G was found to be more frequent 
in lean (62/114) than in obese patients (14/43, chi-square: 
5.957, RR=1.067, 95% CI=1.053–2.651, p=0.015).
Since AHSG has been implicated both with obesity and dia-
betes, further analysis of the genotype and allelic distribution 
among obese and non-obese was performed with respect to 
diabetes (Table 5). Association between BMI and rs4918 poly-
morphism (CC, CG, and GG genotypes, and G allele) could be 
observed among patients without diabetes but not in diabet-
ics. In addition, a strong linearity between the frequency of 
the G allele and lower BMI could be identified. Subgroup anal-
ysis of the anthropometric and metabolic parameters in obese 
patients according to different genotypes and alleles did not 
result in significant statistical differences (data not shown).
Parameter
Obese
(n=48)
Non-obese
(n=109)
p*
AHSG (mg/l)  699±126  661±105 0.053
BMI (kg/m2)  23.1±2.9  26.0±2.4 <0.001
Abdominal circumference (cm)  112±8  98±10 <0.001
Waist circumference (cm)  111±8  102±7 <0.001
Waist/hip ratio  1.00±0.07  0.96±0.08 <0.001
Total cholesterol (mmol/l)  5.20±1.31  5.29±1.14 0.520
LDL-cholesterol (mmol/l)  3.14±0.99  3.20±0.90 0.653
HDL-cholesterol (mmol/l)  1.14±0.23  1.22±0.29 0.107
Triglyceride (mmol/l)  1.99±1.04  1.80±0.95 0.066
TNFa (pg/ml)  6.69±1.77  5.91±1.72 0.009
Adiponectin (µg/ml)  8.53±4.78  9.24±4.12 0.198
Resistin (ng/ml)  11.6±8.13  8.96±5.58 0.057
Leptin (ng/ml)  38.1±20.5  29.9±17.4 0.122
C-peptide (ng/ml)  3.76±2.41  3.10±2.10 0.097
Glucose (mmol/l)  5.69±1.47  5.70±1.71 0.553
Insulin (µU/ml)  27.0±16.9  22.4±14.8 0.106
Table 4. Cohort 2: Comparison of laboratory parameters (mean±SD) of obese and non-obese patients (mean±SD).
* Mann-Whitney test.
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Table 5. Cohort 2: Association between BMI and rs4918 polymorphism. A: genotypes (CC, CG, GG), B: distribution of the G allele.
Genotype
BMI (kg/m2)
Total
0–25 26–29 30–39 40 or more
Patients without diabetes
CC 13 22 22 0 57
CG 16 20 4 0 40
GG 5 4 2 1 12
Total 34 46 28 1 109
Chi square: 19.671, p=0.003
Linear-by-linear association value: 4.416, p=0.036
Patients with diabetes
CC 7 8 9 0 24
CG 6 5 9 1 21
GG 1 2 0 0 3
Total 14 15 18 1 48
Chi square: 4.201, p=0.649
Linear-by-linear association value: 0.011, p=0.918
All patients in cohort 2
CC 20 30 31 0 81
CG 22 25 13 1 61
GG 6 6 2 1 15
Total 48 61 46 2 157
Chi square: 11.479, p=0.075
Linear-by-linear association value: 3.314, p=0.075
Allele
BMI (kg/m2)
Total
0–25 26–29 30–39 40 or more
Patients without diabetes
G 21 24 26 1 52
Non-G 13 22 22 0 57
Total 34 46 28 1 109
Chi square: 11.908, p=0.008
Linear-by-linear association value: 7.420, p=0.006
Patients with diabetes
G 7 7 9 1 24
Non-G 7 8 9 0 24
Total 14 15 18 1 48
Chi square: 1.067, p=0.785
Linear-by-linear association value: 0.111, p=0.739
All patients in cohort 2
G 28 31 15 2 76
Non-G 20 30 31 0 81
Total 48 61 46 2 157
Chi square: 11.479, p=0.075
Linear-by-linear association value: 3.314 p=0.075
Mantel-Haenszel statistics
A
B
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Analysis of non-obese, non-diabetic patients in cohort 2
In order to eliminate the confounding effects of diabetes and 
obesity, we analyzed non-obese, non-diabetic patients sepa-
rately in cohort 2 (n=83). On comparison of patients with the 
CC (n=37), CG (n=37) and GG genotypes (n=9), no significant 
differences were observed. Patient with G allele (n=37), how-
ever, still had significantly lower waist circumference (103±6.8 
vs. 99±7.3 cm, p=0.026) and mildly lower BMI (25.3±2.6 vs. 
26.5±2.3 kg/m2, p=0.048) than the non-G carriers (n=46). Other 
parameters showed no differences (data not shown).
Discussion
Our results suggest that in rs4918 SNP of AHSG, the presence 
of the G nucleotide is associated with lower serum TNFa and 
adiponectin and higher leptin concentrations in cohort 1 com-
pared to that of the C nucleotide. In cohort 2, waist circumfer-
ence and BMI values were lower in G-carriers than in C-carriers. 
In cohort 2, the association between the rs4918 polymorphism 
and obesity was relevant only in patients without diabetes. The 
small sample size could not allow analysis in the diabetic sub-
group. The link between obesity parameters and the rs4918 
polymorphism, however, could still be observed among non-
obese and non-diabetic patients. Leanness, again, was asso-
ciated with higher prevalence of the G allele.
There were obvious differences between the anthropometric, 
metabolic, adipokine, and other cytokine levels of the two co-
horts; therefore, we did not intend to compare them. Cohort 1 
consisted of healthy individuals with normal BMI (below 25), 
whereas members in cohort 2 were chosen based on a hard 
cardiovascular endpoint (myocardial infarction) and had mul-
tiple cardiovascular risk factors (vascular disease, obesity, di-
abetes, and elevated proinflammatory cytokine levels).
Reports on AHSG rs4918 (Thr256Ser) polymorphism are con-
tradictory. The rs4917 TT and rs4918 GG haplotypes, along 
with rs2593813: G, conferred an increased likelihood of lean-
ness in Swedish men [22]. We also found the minor T allele of 
rs4917 was more frequent among lean patients [25]. On the 
other hand, others found the G allele less advantageous. In a 
follow-up study on dialysis patients, the CG and GG genotypes 
were associated with lower AHSG levels and slightly increased 
mortality; however, no causative effect on lethal outcome was 
observed [37]. The rs4918 G allele was associated with low-
er serum AHSG levels [23], the latter being a determinant of 
aortic calcification and high mortality in renal transplant pa-
tients [34]. Similarly, Ma and others found the G allele confers 
a higher risk for ischemic stroke than the C allele [35]. In ad-
dition, they found a higher frequency of the GG genotype and 
the G allele in patients with ischemic stroke or atherosclerotic 
cerebral infarction than in healthy controls in a Northern Han 
Chinese population [35].
There are increasing number of observations suggesting that 
ethnic differences may explain the contradictory effects of dif-
ferent AHSG genotypes and their putative function. It is known 
that the minor variant AHSG-2 is linked with higher estradiol 
levels and higher bone density in Caucasian women [38,39]. 
Jiang and others found evidence of linkage between the AHSG-
SacI polymorphism (rs4918) and bone geometry in Caucasians, 
but not in Chinese [40]. Other studies also demonstrated sig-
nificant differences between genes determining bone density 
in the Caucasian and Chinese populations [41,42].
In theory, change in its serum concentrations or altered mo-
lecular structure or function of AHSG (or both) may explain 
the different activities of the rs4918 variants.
Elevated AHSG levels play a role in the development of obe-
sity and insulin resistance [6–10,14]. Since the first report on 
AHSG SNP-s, including rs4918 [23], several other studies have 
confirmed that minor variants of AHSG (AHSG2) are linked 
with lower serum AHSG levels [19,20,22]. In spite of the small 
sample size, we also noticed a similar trend in cohort 2. The 
mean of the AHSG levels was lower in the GG than in the CC 
in cohort 2, although the difference was not statistically sig-
nificant, probably because of the small sample size.
Elevated serum AHSG is also associated with increased risk of 
diabetes [11,12,43] but this association is not as clear as that 
with non-diabetic healthy or obese individuals [27,44]. Jensen 
et al. found that serum AHSG concentration was inversely cor-
related with cardiovascular mortality in old, non-obese, non-
diabetic individuals [27]. This trend was reversed in diabetes. 
Obesity and insulin resistance had similar modifying effects in 
individuals without diabetes. Thus, the association with elevat-
ed AHSG and lower mortality was present only in non-obese 
persons with normal HOMA-IR below the median value [27].
In the EPIC Potsdam Study, Fisher et al. observed a strong associ-
ation between the C allele of rs4917 and occurrence of myocar-
dial infarction [19]. They suggested the pathogenic role of AHSG 
in the development of cardiovascular diseases. We found no sta-
tistically significant differences of rs4918 genotypes and alleles 
between the two small cohorts we studied. Nevertheless, it is 
remarkable that in cohort 1 (healthy persons with normal BMI), 
TNFa levels significantly differed among rs4918 homozygotes 
and the G was associated with lower TNFa and adiponectin and 
higher leptin levels than the C allele. These differences could not 
be detected in cohort 2, probably because of the existing sub-
clinical inflammation and prevalence of obesity among patients. 
Signal transduction changes in the peri-infarct area may also 
affect infarct size and post-infarction cardial remodelling [45].
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In theory, the rs4918 polymorphism, which affects the intron 
7 of the molecule (D3 domain region), may also result in al-
tered function of the molecule. It has been demonstrated that 
the TT variant of rs4917 has 35 times higher lipolytic sensitivi-
ty than its CC variant, but no functional differences for rs4918 
have been reported [46]. Since AHSG connects metabolic and 
inflammatory processes by linking FFAs and TLR4-s, it seems 
relevant to investigate the FFA and TLR4 binding activities of 
the various rs4918 AHSG polymorphisms [15–17].
One limitation of our study is that the sample size did not al-
low for subgroup analysis, especially the minor (G) nucleotide 
frequency in cohort 2. Secondly, the cross-sectional design did 
not allow drawing causal relationships between rs4918 poly-
morphism and the parameters we investigated. The obligatory 
antilipemic (mainly with statins), platelet aggregation inhibit-
ing (salicylates, clopidogrel), and antidiabetic treatment (bed-
time insulin) may mask the differences in serum AHSG concen-
trations and their correlation with rs4918 variants in cohort 2.
Conclusions
Our observations (made in a Caucasian population) are in line 
with those suggesting that the minor variant G of rs4918 is 
linked with more favorable parameters than is the C allele. In 
addition, AHSG seems to be correlated much more with obe-
sity than with diabetes mellitus. Large-scale prospective stud-
ies could determine the causative relationship and functional 
impact of AHSG variants in different populations.
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